

# Alastair D Lamb

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3817118/publications.pdf>

Version: 2024-02-01

50  
papers

2,188  
citations

304602

22  
h-index

233338

45  
g-index

56  
all docs

56  
docs citations

56  
times ranked

4283  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Androgen Receptor Induces a Distinct Transcriptional Program in Castration-Resistant Prostate Cancer in Man. <i>Cancer Cell</i> , 2013, 23, 35-47.	7.7	354
2	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. <i>Lancet Oncology</i> , The, 2014, 15, 1521-1532.	5.1	291
3	Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. <i>EBioMedicine</i> , 2015, 2, 1133-1144.	2.7	260
4	Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2020, 78, 402-414.	0.9	183
5	Meta-analysis showing the beneficial effect of $\alpha$ -blockers on ureteric stent discomfort. <i>BJU International</i> , 2011, 108, 1894-1902.	1.3	104
6	HES6 drives a critical $\alpha$ -AR transcriptional programme to induce castration-resistant prostate cancer through activation of an $\alpha$ -E $\alpha$ 2 $\alpha$ -F $\alpha$ 1-mediated cell cycle network. <i>EMBO Molecular Medicine</i> , 2014, 6, 651-661.	3.3	74
7	Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype. <i>Oncogene</i> , 2014, 33, 5666-5674.	2.6	74
8	“TREXIT 2020” why the time to abandon transrectal prostate biopsy starts now. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 62-65.	2.0	68
9	Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. <i>Nature Communications</i> , 2021, 12, 5307.	5.8	58
10	The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer. <i>European Urology</i> , 2016, 70, 214-218.	0.9	56
11	Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. <i>British Journal of Cancer</i> , 2020, 123, 1089-1100.	2.9	51
12	Identification of potential therapeutic targets in prostate cancer through a cross-species approach. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	46
13	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. <i>European Urology</i> , 2017, 71, 381-388.	0.9	41
14	The transcriptional programme of the androgen receptor ( $\alpha$ -AR) in prostate cancer. <i>BJU International</i> , 2014, 113, 358-366.	1.3	38
15	Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv371.	3.0	37
16	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. <i>European Urology</i> , 2017, 72, 22-31.	0.9	37
17	Systematic Review of Studies Reporting Positive Surgical Margins After Bladder Neck Sparing Radical Prostatectomy. <i>Current Urology Reports</i> , 2017, 18, 99.	1.0	34
18	The ETS family member GABP $\alpha$ modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer. <i>Nucleic Acids Research</i> , 2014, 42, 6256-6269.	6.5	33

#	ARTICLE	IF	CITATIONS
19	Mining Human Prostate Cancer Datasets: The <i>œcamcAPP</i> Shiny App. <i>EBioMedicine</i> , 2017, 17, 5-6.	2.7	31
20	DESNT: A Poor Prognosis Category of Human Prostate Cancer. <i>European Urology Focus</i> , 2018, 4, 842-850.	1.6	30
21	Local anaesthetic transperineal (LATP) prostate biopsy using a probe-mounted transperineal access system: a multicentre prospective outcome analysis. <i>BJU International</i> , 2021, 128, 311-318.	1.3	28
22	Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial. <i>BJU International</i> , 2022, 130, 43-53.	1.3	26
23	Optimizing prostate biopsy techniques. <i>Current Opinion in Urology</i> , 2019, 29, 578-586.	0.9	23
24	Social Media Coverage of Scientific Articles Immediately After Publication Predicts Subsequent Citations - #SoME_Impact Score: Observational Analysis. <i>Journal of Medical Internet Research</i> , 2020, 22, e12288.	2.1	19
25	Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management. <i>BJUI Compass</i> , 2021, 2, 13-23.	0.7	18
26	A Systematic Review of Prostate Cancer Heterogeneity: Understanding the Clonal Ancestry of Multifocal Disease. <i>European Urology Oncology</i> , 2021, 4, 358-369.	2.6	16
27	Early Online Attention Can Predict Citation Counts for Urological Publications: The #UroSoMe_Score. <i>European Urology Focus</i> , 2020, 6, 458-462.	1.6	15
28	Harnessing the potential of multimodal radiotherapy in prostate cancer. <i>Nature Reviews Urology</i> , 2020, 17, 321-338.	1.9	15
29	Morphological Features Extracted by AI Associated with Spatial Transcriptomics in Prostate Cancer. <i>Cancers</i> , 2021, 13, 4837.	1.7	15
30	Evolution and oncological outcomes of a contemporary radical prostatectomy practice in a regional tertiary referral centre. <i>BJU International</i> , 2016, 118, 779-784.	1.3	14
31	Zinc stable isotopes in urine as diagnostic for cancer of secretory organs. <i>Metallomics</i> , 2021, 13, .	1.0	12
32	Changing face of robot-assisted radical prostatectomy in Melbourne over 12 years. <i>ANZ Journal of Surgery</i> , 2018, 88, E200-E203.	0.3	11
33	Towards <i>œnext-generation</i> prostate cancer screening. <i>Lancet Oncology</i> , The, 2015, 16, 1579-1580.	5.1	9
34	Pheochromocytoma with Negative Metanephrines: A Rarity and the Significance of Dopamine Secreting Tumors. <i>Urology Case Reports</i> , 2017, 12, 51-53.	0.1	9
35	A cross-section of UK prostate cancer diagnostics during the coronavirus disease 2019 (COVID-19) era <i>œ</i> a shifting paradigm?. <i>BJU International</i> , 2021, 127, 30-34.	1.3	9
36	Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer. <i>British Journal of Cancer</i> , 2021, 125, 534-546.	2.9	8

#	ARTICLE	IF	CITATIONS
37	Prostatic capsular incision during radical prostatectomy has important oncological implications: a systematic review and meta-analysis. <i>BJU International</i> , 2019, 124, 554-566.	1.3	7
38	Aiming for a holistic integrated service for men diagnosed with prostate cancer – Definitions of standards and skill sets for nurses and allied healthcare professionals. <i>European Journal of Oncology Nursing</i> , 2017, 29, 31-38.	0.9	4
39	First Report of Prostate-specific Membrane Antigen-targeted Immunotherapy in Prostate Cancer: The Future is Bright. <i>European Urology</i> , 2018, 73, 653-655.	0.9	4
40	Re: Diagnostic Accuracy of Multi-parametric MRI and TRUS Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study. <i>European Urology</i> , 2017, 72, 151.	0.9	3
41	The phylogenetic future of prostate cancer staging: PSMA-PET and the dandelion theory. <i>Future Oncology</i> , 2017, 13, 1801-1807.	1.1	3
42	Orient Expression: Solving the Mystery of Asian Prostate Cancer?. <i>European Urology</i> , 2018, 73, 340-342.	0.9	3
43	Use of intraoperative fluorescence to enhance robot-assisted radical prostatectomy. <i>Future Oncology</i> , 2021, 17, 1083-1095.	1.1	3
44	The Use of Digital Pathology and Artificial Intelligence in Histopathological Diagnostic Assessment of Prostate Cancer: A Survey of Prostate Cancer UK Supporters. <i>Diagnostics</i> , 2022, 12, 1225.	1.3	3
45	Practical Polling for Prostate Cancer: AR-V7-based Treatment Selection. <i>European Urology</i> , 2017, 71, 883-885.	0.9	2
46	Disrupting the Status Quo in Prostate Cancer Diagnosis. <i>European Urology</i> , 2017, 71, 193-194.	0.9	2
47	Editorial Comment to White blood cell count is positively associated with benign prostatic hyperplasia. <i>International Journal of Urology</i> , 2014, 21, 312-312.	0.5	0
48	Is there a link between cycling and prostate cancer?. <i>Trends in Urology &amp; Men's Health</i> , 2015, 6, 40-41.	0.2	0
49	Reducing Mortality in the Ageing Patient: Treatment of the Primary Tumour Is Not Necessary. <i>European Urology Focus</i> , 2017, 3, 328-329.	1.6	0
50	Genetic Reasons to Walk the Extra Mile to Prevent Prostate Cancer. <i>European Urology</i> , 2019, 76, 41-42.	0.9	0